Editorial
Neoadjuvant immunotherapy for non-small cell lung cancer: can early intervention result in durable clinical benefit?
Abstract
Management of patients with locally advanced non-small cell lung cancer (NSCLC) often relies on multimodality treatment that includes surgical resection in appropriate cases and peri-operative chemotherapy with or without radiation therapy.